Status:

UNKNOWN

GVAX in Advanced Prostate Cancer Patients Made Lymphopenic

Lead Sponsor:

Providence Health & Services

Collaborating Sponsors:

Providence Cancer Center, Earle A. Chiles Research Institute

Cell Genesys

Conditions:

Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

Androgen (a male sex hormone) deprivation is the standard therapy for metastatic prostate cancer and results in regression or control of disease in 80-85% of patients. This hormone therapy results in ...

Detailed Description

Other investigators have focused on tumor cell-based vaccine strategies using either allogeneic or autologous tumor cells. Vaccines derived from allogeneic melanoma tumor cell lines are associated wit...

Eligibility Criteria

Inclusion

  • Histologically diagnosed adenocarcinoma of the prostate
  • Progressive disease
  • ECOG performance status of 0 or 1
  • Adequate bone marrow, renal and hepatic function
  • Castrate levels of testosterone
  • May have had local radiotherapy as part of their initial treatment or 28 days after palliative radiotherapy or one chemotherapy treatment for metastatic disease

Exclusion

  • Transitional cell, small cell or squamous cell prostate cancer
  • Systemic steroid therapy within 10-days of enrollment
  • Documented history of active autoimmune disease such as lupus, sarcoidosis, rheumatoid arthritis, glomerulonephritis or vasculitis
  • Clinically significant active infections
  • History of other malignancies over past 5-years (except non-melanoma skin cancer or controlled superficial bladder cancer)
  • Uncontrolled medical problems (i.e. neurological, cardiovascular) considered high risk for investigational new drug treatment
  • Prior treatment with an investigational drug within 30-days of study entry
  • Seropositive for HIV, hepatitis B surface antigen or hepatitis C

Key Trial Info

Start Date :

July 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2005

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT00122005

Start Date

July 1 2005

End Date

July 1 2005

Last Update

February 24 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Providence Portland Medical Center

Portland, Oregon, United States, 97213